Treatment with tirzepatide demonstrated a 38% decrease in the risk of heart failure outcomes (composite endpoint) compared with placebo. Detailed results were announced from the phase 3 SUMMIT trial ...
The hypoparathyroidism treatment space has made a buzz in 2024 with a major drug approval, acquisitions, and big advances in ...
A relatively easy way to encourage your Black patients with MS to participate in clinical research is to introduce them to ...
“Time Off for Clinical Trials," launched on Nov. 20, sees six of BioNJ’s biggest members—Amicus Therapeutics, Bristol Myers ...
Melt Pharmaceuticals announced positive results from its Phase 3 study of MELT-300, a non-IV, non-opioid tablet for ...
Combining magnetic and direct current transcranial stimulations was more effective than either treatment alone for major ...
The Brighterside of News on MSN2h
Groundbreaking clinical trial cures cancer in 100% of patientsIn a clinical trial involving 14 participants, immunotherapy on its own effectively eradicated rectal cancer. This ...
During the Phase III BROOKLYN trial, patients were randomly assigned in a 2:1 ratio to receive either obicetrapib 10mg or a ...
Aelis Farma announced positive results from Phase 1/2 trial of its drug candidate AEF0217 in young adults with Down syndrome.
Donald Trump’s return to the White House presents an opportunity to overhaul federal dietary guidelines, which lack ...
Backed by a Strong Balance Sheet, MIRA Accelerates Toward Becoming a Clinical-Stage Company and Advancing Breakthroughs in Pain and Depression Treatment ...
Viking Therapeutics (VKTX) announced that final results from the company’s Phase 2b clinical trial of VK2809, the company’s novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback